SHARE

Lucida Medical raises £8.7m to scale AI-led cancer diagnostics platform

The UK-based healthtech company has secured £8.7m in funding to expand its AI platform supporting faster prostate cancer diagnosis from MRI scans. The round was led by IW Capital with backing from XTX Ventures and Macmillan Cancer Support.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.